ReviewIndian dermatology online journal
Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology.
Review in Indian dermatology online journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparative study between efficacy of topical tofacitinib 2% ointment versus topical clobetasol propionate 0.05% ointment in hand eczema at a tertiary hospital in central India.F1000Research · 2024Trial
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes.Journal of personalized medicine · 2026Review
- Recent Advances in Vitiligo Treatment.ImmunoTargets and therapy · 2026Review
- JAK Inhibitors for the Treatment of Vitiligo: Current Evidence and Emerging Therapeutic Potential.Drugs · 2025Review
- Article
- The JAK-STAT Signaling Pathway in Epilepsy.Current neuropharmacology · 2023Review
- Role of Janus Kinase Inhibitors in Therapy of Psoriasis.Journal of clinical medicine · 2021Review
- Cutaneous sıde-effects of the potential COVID-19 drugs.Dermatologic therapy · 2020Review
- A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata.International journal of trichologyArticle
- Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata.International journal of trichologyArticle
- Small Molecules in the Management of Psoriasis and Psoriatic Arthritis.Indian journal of dermatologyArticle
- Response to Oral Tofacitinib in Childhood Refractory Nipple Eczema.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or sustaining intolerable adverse effects with the classical immunosuppressives and other targeted therapies such as the biologics. The most common dermatoses for which oral as well as topical Jakinibs such as tofacitinib have been evaluated and are being used albeit as an off-label indication include psoriasis, psoriatic arthritis, alopecia areata, vitiligo, and atopic dermatitis. This article provides a succinct review on the current status of oral tofacitinib in dermatology through literature search of PubMed database and stresses on the need for further evidence generation to define the drug's place in the therapeutic arsenal of dysimmune cutaneous disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.